PERSONALIZED APROACH TO POSTOPERATIVE CHEMOTHERAPY IN THE COMBINED MODALITY TREATMENT OF NON-SMALL CELL LUNG CANCER (CLINICAL CASE)
https://doi.org/10.21294/1814-4861-2016-15-3-97-101
Abstract
We present a clinical case of non-small cell lung cancer treated with personalized adjuvant chemotherapy. The expression levels of drug resistance genes, such as ABCC5, RRM1, ERCC1, TOP1, TOP2a, TUBB3 and TYMS in tumor tissue from non-small cell lung cancer were used as predictive markers. This case shows the usefulness of determination of the expression of drug resistance genes before and after preoperative chemotherapy, and it is important in terms of determining the individual sensitivity of the tumor to chemotherapy drugs, thus allowing the treatment plan for the individual patient to be tailored.
About the Authors
E. O. Rodionov
Tomsk Cancer Research Institute, Tomsk
Russian Federation
Postgraduate of Thoracal and Abdominal Department
Russian Federation
Postgraduate of Thoracal and Abdominal Department
S. V. Miller
Tomsk Cancer Research Institute, Tomsk
Russian Federation
MD, DSc, Leading Researcher, Thoracal and Abdominal Department
Russian Federation
MD, DSc, Leading Researcher, Thoracal and Abdominal Department
M. M. Tsyganov
Tomsk Cancer Research Institute, Tomsk, Tomsk State University, Tomsk
Russian Federation
Junior Researcher, Laboratory of Viral Oncology
Russian Federation
Junior Researcher, Laboratory of Viral Oncology
O. V. Cheremisina
Tomsk Cancer Research Institute, Tomsk
Russian Federation
MD, DSc, Head of Endoscopy Department
Russian Federation
MD, DSc, Head of Endoscopy Department
S. A. Tuzikov
Tomsk Cancer Research Institute, Tomsk, Siberian State Medical University, Tomsk
Russian Federation
MD, DSc, Professor, Head of Thoracal and Abdominal Department
Russian Federation
MD, DSc, Professor, Head of Thoracal and Abdominal Department
N. V. Litvyakov
Tomsk Cancer Research Institute, Tomsk, Tomsk State University, Tomsk
Russian Federation
DSc, Head of Laboratory of Viral Oncology
Russian Federation
DSc, Head of Laboratory of Viral Oncology
I. G. Frolova
Tomsk Cancer Research Institute, Tomsk
Russian Federation
MD, Professor, Head of Diagnostic Imaging Department
Russian Federation
MD, Professor, Head of Diagnostic Imaging Department
S. A. Velichko
Tomsk Cancer Research Institute, Tomsk
Russian Federation
MD, Professor, Principal Researcher, Diagnostic Imaging Department,
Russian Federation
MD, Professor, Principal Researcher, Diagnostic Imaging Department,
P. I. Lukyanenok
Cardiology Research Institute, Tomsk
Russian Federation
MD, DSc., Senior Researcher, MRI laboratory
Russian Federation
MD, DSc., Senior Researcher, MRI laboratory
T. V. Polishchuk
Tomsk Cancer Research Institute, Tomsk
Russian Federation
MD, PhD, Researcher, Thoracal and Abdominal Department
Russian Federation
MD, PhD, Researcher, Thoracal and Abdominal Department
References
1. Trahtenberg A.H., Kolbanov K.I. Lung Cancer. M., 2012. 176 p. [in Russian]
2. Shatokhina, S.N., Zakharova N.M., Dedova M.G., Sambulov V.I., Shabalin V.N. Morphological marker of tumor progression in laryngeal cancer // Voprosy onkologii. 2013. Vol. 59 (2). P. 66–70. [in Russian]
3. Jumov E.L., Cyganov M.M., Litvjakov N.V., Polishhuk T.V., Miller S.V., Rodionov E.O., Tuzikov S.A. Gene expression of multidrug resistance in non-small cell lung cancer // Sibirskij onkologicheskij zhurnal. 2014. № 1. P. 16–22. [in Russian]
4. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., Postmus P.E., Rusch V., Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours // J. Thorac. Oncol. 2007. Vol. 2. P. 706–714.
5. Lan J., Huang H.Y., Lee S.W., Chen T.J., Tai H.C., Hsu H.P., Chang K.Y., Li C.F. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma // Tumor Biol. 2014. Vol. 35 (1). P. 179–187. doi: 10.1007/s13277-013-1022-6.
6. Wei C.H., Gorgan T.R., Elashoff D.A., Hines O.J., Farrell J.J., Donahue T.R. A meta-analysis of gemcitabine biomarkers in patients with pancreatico-biliary cancers // Pancreas. 2013. 42 (8). P. 1303–1310. doi: 10.1097/MPA.0b013e3182a23ae4.
7.
8.
Review
For citations:
Rodionov E.O., Miller S.V., Tsyganov M.M., Cheremisina O.V., Tuzikov S.A., Litvyakov N.V., Frolova I.G., Velichko S.A., Lukyanenok P.I., Polishchuk T.V. PERSONALIZED APROACH TO POSTOPERATIVE CHEMOTHERAPY IN THE COMBINED MODALITY TREATMENT OF NON-SMALL CELL LUNG CANCER (CLINICAL CASE). Siberian journal of oncology. 2016;15(3):97-101. (In Russ.) https://doi.org/10.21294/1814-4861-2016-15-3-97-101
Views:
830
Email this article 
